RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Thanks Neuro. From what I've read (Feuerstein articles), the plan is to file the NDA based on this Medivation-designed trial (if positive) plus the Pfizer-designed Phase 3 that should be completed later in the year. And Pfizer is apparently running combo trials with Namenda as well as with Aricept.

Medivation stands to get a $500 mil payment upon approval (!), to go with the $225 mil in upfronts they got in 2008.

Dimebon's MOA is interesting. It looks like it affects numerous pathways, including AMPA, and was used as an antihistimine years ago in Russia -

>>> Dimebon appears to operate through multiple mechanisms of action, both blocking the action of neurotoxic beta-amyloid proteins and inhibiting L-type calcium channels,[14] modulating the action of AMPA and NMDA glutamate receptors,[15] and may exert a neuroprotective effect by blocking a novel target that involves mitochondrial pores,[16] which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process.[17] It also blocks a number of other receptors including alpha-Adrenergic receptors and the serotonin receptor subtypes 5-HT2C, 5-HT5A and 5-HT6.[18] Dimebon lacks anticholinergic effects. <<<


Since Pfizer's own Phase 3s might conceivably achieve FDA approval in spite of a failure of the Medivation-designed Phase 3, one could imagine the mother of all buying opportunities if the Medivation trial were to flop, and Medivation stock implodes, only to rise again spectacularly later in 2010 upon favorable Pfizer study results. I guess stranger things have happened.